Kailera Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
CPP Investment Board and its subsidiary, CPP Investment Board Private Holdings (4) Inc., have reported beneficial ownership of 7,304,688 shares, representing 5.6% of Kailera Therapeutics, Inc.'s common stock.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 8.3% of Kailera Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has reported a beneficial ownership of 8.9% in Kailera Therapeutics, Inc., acquiring 11,511,853 shares.